{"id":"AGY-FED-HEALTH-OTHER-021","kind":"context","level":"federal","jurisdiction":"United States (federal); Drug Enforcement Administration, Diversion Control Division","state":"","metro":"","industry":"","agency":"FED-HEALTH-OTHER","eco":"","issuer":"Drug Enforcement Administration, Diversion Control Division (guidance document EO-DEA213)","authority":"21 U.S.C. 822(e), 802(10); 21 C.F.R. 1301.12(a)","instrument":"DEA-DC-043 (EO-DEA213), guidance: Administering certain controlled substances in the parking lot of a health care provider\u0027s DEA-registered location during the COVID-19 public health emergency","title":"Administering Certain CS in the parking lot of a healthcare provider\u0027s DEA-registered location during the COVID-19 public health emergency","dateIssued":"2020-07-28","effective":"2020-07-28","end":"For the duration of the public health emergency","startDate":"2020-07-28","endDate":"2021-09-30","quarters":["2020Q3","2020Q4","2021Q1","2021Q2","2021Q3"],"types":["HC","OTHER"],"addressees":["REMS-certified health care providers registered with DEA"],"clause":"The Food and Drug Administration (FDA) made an allowance for certain Risk Evaluation and Mitigation Strategies (REMS)-certified healthcare providers (HCPs) to provide medically supervised treatment in the patient\u0027s home during the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. As an alternative to this, would DEA allow HCPs to administer REMS-designated controlled substances to patients in the parking lot at the HCPs\u0027 DEA-registered locations? Answer:... DEA will allow the administration of REMS-designated controlled substances in the parking lot of the registered location during the COVID-19 public health emergency, subject to the conditions stated.","enforcement":"Registration and dispensing requirements under 21 U.S.C. 822 and 842","functions":["CL clinical administration","SF premises (parking-lot care)","CB patients"],"notes":"Behavioral-health and pain clinics administering esketamine and similar REMS drugs moved administration outdoors.","sourceUrl":"https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-043)(EO-DEA213)_QA_Administering_CS_in_vehicles_during_COVID-19_(Final).pdf","snapshot":"https://web.archive.org/web/20201001134857/https://www.deadiversion.usdoj.gov/GDP/(DEA-DC-043)(EO-DEA213)_QA_Administering_CS_in_vehicles_during_COVID-19_(Final).pdf","fileExists":true,"fileBytes":91362,"grade":"primary","character":"context","description":"","collection":"AGY-FED-HEALTH-OTHER","url":"/library/AGY-FED-HEALTH-OTHER-021","exhibitUrl":"/exhibit/AGY-FED-HEALTH-OTHER-021","citation":"Drug Enforcement Administration, Diversion Control Division (guidance document EO-DEA213), DEA-DC-043 (EO-DEA213), guidance: Administering certain controlled substances in the parking lot of a health care provider\u0027s DEA-registered location during the COVID-19 public health emergency (July 28, 2020) (Ex. AGY-FED-HEALTH-OTHER-021)","stateName":"","related":[]}